Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $17.6 million, a 21% increase from $14.9 million in Q3 2024, driven by the successful launch of Emrosi [13][18] - Gross margin decreased to 67.4% in Q3 2025 from 69.4% in Q3 2024, but showed steady improvement from 63.5% in Q1 to 67.1% in Q2 [14][15] - GAAP net loss was $2.3 million, or $0.09 per share, compared to a loss of $2.4 million, or $0.12 per share, in the same period last year [15] - EBITDA improved from a loss of $1 million in Q3 2024 to a loss of $500,000 in Q3 2025, while adjusted EBITDA was positive at $1.7 million [16] Business Line Data and Key Metrics Changes - Emrosi contributed $4.9 million in Q3 2025, a 75% increase compared to Q2 2025, with total prescriptions growing approximately 146% [5][6] - Legacy products, including Qbrexa, Accutane, and Amzeeq, saw a 16% year-over-year decline in revenue due to generic competition impacting Accutane [5] - Amzeeq's total prescription growth indicates strong commercial execution, with a one-to-one ratio of refills to new prescriptions [8][9] Market Data and Key Metrics Changes - Over $100 million of the $187 million commercial lives currently have access to Amzeeq, with successful contracting with two of the three largest GPOs [7] - The number of unique prescribers for Emrosi increased by approximately 50% to over 2,700, demonstrating substantial progress in product adoption [9] Company Strategy and Development Direction - The company aims to position Emrosi as the standard of care for rosacea treatment, targeting peak annual net sales of over $200 million in the U.S. and over $300 million globally [18] - Focus on disciplined expense management and margin expansion to improve profitability and sustain revenue growth [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable EBITDA positivity in Q4 2025, indicating a transformational year for the company [18] - Positive physician feedback on Emrosi suggests strong initial adoption and potential for continued growth [8][50] Other Important Information - The company is actively participating in key dermatology medical conferences to build awareness and momentum for Emrosi [9][10] - The copay assistance program is currently bridging the gap until broader health plan formulary adoption occurs [7] Q&A Session Summary Question: Usage of patient assistance program for Amzeeq - Management noted that the copay assistance program will see reduced reliance as reimbursement improves, with significant gains expected in 2026 [22][23] Question: Focus on breadth vs. depth of prescribers - The strategy involves both expanding the number of prescribers and increasing the volume of prescriptions from existing prescribers, with expectations for a snowball effect as confidence builds [25][26] Question: Revenue per script fluctuations - Management acknowledged variability in gross to net revenue due to early-stage dynamics and expected improvements with the addition of the third GPO in early 2026 [33][34] Question: Launch curve perspective - All indicators suggest a positive and potentially accelerating launch curve, with expectations for increased new prescriptions and refills [40][41] Question: Accutane's performance amidst generic competition - Management indicated that Accutane appears stable, with a recent uptick in performance, although competition remains a factor [42] Question: Retention rate of prescribers - No specific retention data was provided, but management noted ongoing trial and adoption among new prescribers [46][50] Question: Qbrexa's growth management - Qbrexa is expected to maintain single-digit growth year-over-year, with effective management of the overlap with Amzeeq [51]

Financial Data and Key Metrics Changes - At the end of Q3 2025, the company reported approximately $329.3 million in cash, cash equivalents, and marketable securities, providing a runway through 2027 [6][25][28] - R&D expenses increased compared to Q3 2024, primarily due to higher spending in the HCV clinical development program [24] - G&A expenses decreased in Q3 2025 compared to Q3 2024, driven by lower stock-based compensation [24] Business Line Data and Key Metrics Changes - The global phase 3 program for HCV treatment is on track, with patient enrollment for the North American trial expected to complete next month [4][14] - The company is expanding its antiviral hepatitis pipeline to include candidates for hepatitis E, addressing a significant unmet medical need [5][18] Market Data and Key Metrics Changes - The global HCV market is approximately $3 billion in annual net sales, with the company aiming to disrupt and expand this market with its new treatment regimen [28] - The hepatitis E market opportunity could translate into roughly $500 million to $750 million per year or more, given the high incidence of infections [20][21] Company Strategy and Development Direction - The company is focused on completing its phase 3 trials for HCV, which are expected to drive shareholder value and catalyze business development discussions [25][27] - The introduction of a new regimen for HCV treatment is positioned as a potential best-in-class option, with a differentiated profile and a unique dual mechanism of action [12][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong execution of the phase 3 program and the potential for the new treatment to become the most prescribed for hepatitis C [28] - The company highlighted the importance of addressing the unmet needs of immunocompromised patients living with hepatitis E, indicating a strategic expansion of its antiviral pipeline [5][18] Other Important Information - The company completed a share repurchase program, repurchasing $25 million of shares, which were retired and returned to authorized but unissued status [25] - A virtual panel event featuring key opinion leaders in hepatology is scheduled to discuss HCV-related topics, indicating ongoing engagement with the medical community [10][11] Q&A Session Summary Question: How does your recent data set at the liver meeting showing no interaction with famotidine, in addition to your prior data showing no interaction with PPI, increase your differentiation from Epclusa? - Management noted that the contraindication for Epclusa regarding H2-reducing therapy presents a clear problem for patients, making their regimen a significant differentiator [32] Question: There is a chart showing time to undetectable, with genotype three showing a more rapid time to undetectable. Is there any significance in that? - Management confirmed that bemnifosbuvir is more potent against genotype 3, which may relate to the dual mechanism of action [36][37] Question: The compound for hepatitis E does not employ the protide technology. Is that a deliberate decision? - Management clarified that the new candidates utilize a similar prodrug technology as bemnifosbuvir, with a focus on optimizing potency against hepatitis E [39]

Financial Data and Key Metrics Changes - Revenue increased by 8% to $2.9 million compared to $2.7 million a year ago, reflecting steady execution and year-over-year progress [12] - Gross profit rose to $1.9 million, maintaining a strong gross margin of 66%, relatively unchanged year-over-year [12] - Operating expenses were reported at $3.7 million, up from $3.4 million in the prior year, leading to an operating loss of $1.7 million compared to $1.6 million last year [13] - Net loss after preferred stock dividends was $1.7 million, or $2.21 per share, versus a net loss of $1.6 million, or $3,732 per share in the prior year period [13] Business Line Data and Key Metrics Changes - Strong sales to VA partners and a shift towards B2B channels contributed to performance, with significant progress in the VA and government segment [4][5] - New product launches included medicine reminders and activity metrics, enhancing the company's proactive analytics capabilities [5][6] Market Data and Key Metrics Changes - The company is focusing on expanding its VA and government relationships, strengthening B2B distributor networks, and improving direct-to-consumer channels [10][17] - A national safety survey indicated that trust, simplicity, and visibility are key factors for customers when choosing personal safety systems, validating the company's market direction [9] Company Strategy and Development Direction - The company is evolving its business model from standalone device sales to a comprehensive platform that includes subscription monitoring and predictive analytics [3] - Priorities include increasing adoption of bundled monitoring and subscription services, advancing the AI-enabled care platform, and optimizing go-to-market execution [10][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver progress with a solid balance sheet and increasing revenue [17] - The focus remains on executing a targeted business plan with clear priorities, particularly in the VA and government sectors [10][17] Other Important Information - The company has filed 44 patent applications, with 24 issued, strengthening its position as an innovator in personal safety and care technology [8] - The company is currently trading under the symbol LGMKD on the OTC market, with plans to resume trading under the old ticker symbol LGMK [14] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with closing remarks from management [16][18]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 increased 112% to $6.88 million, compared to $3.24 million in Q3 2024 [16] - For the nine months ended 2025, total revenues increased 202% to $17.57 million from $5.82 million in the same period last year [17] - Adjusted EBITDA profitability was achieved one quarter ahead of projections, totaling over $491,000 for Q3 2025 [23] - Net loss for Q3 2025 totaled $1.04 million, a 26% reduction compared to a net loss of $1.4 million for Q3 2024 [21] Business Line Data and Key Metrics Changes - A significant portion of Q3 2025 revenue, approximately $6.59 million, came from recurring services and consulting, with $5.15 million from the asset management agreement with APR Energy [17] - Cost of revenues for Q3 2025 increased 88% to $4.36 million compared to $2.32 million for Q3 2024 [18] - Gross margin for Q3 2025 increased 174% to $2.52 million, compared to $919,000 for Q3 2024 [18] Market Data and Key Metrics Changes - The company is positioned to address the growing demand for edge computing, with discussions ongoing with two to three large developers [5] - The backlog represents nearly $26 million in revenue, with about $9.5 million projected to be recognized in Q4 2025 [25] Company Strategy and Development Direction - The company is pivoting to focus resources into the edge computing space and adding additional data center service offerings [6] - Plans for the future include establishing a standalone Duos business focused on the data center space by 2026 [7] - The company is also in the process of hiring a team to seek business opportunities in the overall data center market [35] Management's Comments on Operating Environment and Future Outlook - Management noted that the asset management agreement with APR Energy has been a major success and contributor to growth during the transition [10] - The company anticipates that growth in the data center market from edge deployments will offset any lower revenues from the asset management agreement in 2026 [11] - The outlook for Duos is promising, with expectations for continued growth and improved financials [38] Other Important Information - The company achieved a significant improvement in liquidity, with over $35 million in cash and short-term receivables as of Q3 2025, up approximately 422% year-over-year [24] - The company has paid off all outstanding debt and master capital leases, leaving nearly $12 million in fixed assets [24] Q&A Session Summary Question: How is growing demand from AI and cloud customers affecting your business? - The growing demand is positively impacting both Duos and APR Energy, with hyperscalers seeking more computing power due to challenges in scaling large data centers [39][40] Question: Can you elaborate on what drove the 112% year-over-year revenue increase and how sustainable this trajectory looks heading into 2026? - The asset management agreement with APR Energy has driven revenue growth, and the company is confident in replacing this revenue with edge data center business and new infrastructure opportunities [42][44] Question: Can you update us on the current progress and timing for the remaining edge data center installations? - Six edge data centers are currently operational, with four more scheduled for installation this month and five more by the end of the year [45] Question: How does the new modular data center patent enhance your competitive advantage? - The patent introduces a clean room environment that protects hardware and meets strict auditing standards, providing a significant competitive edge in the market [46][48] Question: Where are you prioritizing your target markets for edge deployments? - The education sector has been a key focus, with the first contract outside Texas secured in Illinois, driven by the need for better connectivity in Tier 3 and Tier 4 markets [50][51]

Financial Data and Key Metrics Changes - Sales for the first nine months of 2025 were $26.2 million, up $16.9 million, or 182% over the prior year, primarily due to price increases and some volume increase in the zeolite business [6][7] - Gross margin increased by 4 percentage points from 24% last year to 28% this year, although there will be pressure on gross margins in the fourth quarter due to declining antimony market prices [6][7] - Consolidated net loss was $4.1 million for the first nine months, including $5.2 million of non-cash expenses, but operating activities generated positive cash flow when excluding working capital changes [7][8] Business Line Data and Key Metrics Changes - Antimony sales volume increased in October, with consolidated sales of $5.6 million for the month compared to third quarter sales of $8.7 million [6][7] - The company secured a three-year supply agreement for antimony ore and a five-year sole source sales contract with the DLA, enhancing sales capabilities [9][10] Market Data and Key Metrics Changes - The company has developed and executed over 15 separate supply contracts for materials sourced from 10 different countries, with ongoing negotiations with over 30 other parties [28] - Approximately 330 tons of antimony feedstock were received at the smelter in Mexico, with additional shipments expected to ramp up significantly [28][30] Company Strategy and Development Direction - The company aims to be the preferred provider of critical minerals, focusing on growth, diversification, and sustainability [9][10] - Plans include expanding the processing facility in Montana and exploring opportunities in cobalt and tungsten, with a focus on securing government contracts similar to the DLA contract [24][41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating a significant increase in production capacity from 100 tons to 500-600 tons per month [32][60] - The company is focused on overcoming challenges related to material quality and supply chain issues, with expectations of improved efficiency and throughput as new materials are integrated [65][66] Other Important Information - The company reported a significant increase in share price, climbing from about $3.08 to $7.62 per share, marking the best-performing quarter in its history [35][36] - Institutional ownership has increased from almost zero to about 30% over the past year and a half, indicating growing investor interest [36][37] Q&A Session Summary Question: What is the difference between the two types of antimony in the contracts? - The DLA contract is for metallic antimony in ingot form, while the commercial supply contract is for antimony trioxide, which is a white powder [54][55] Question: Is management considering building an additional smelter or processing facility? - The current expansion in Thompson Falls is the maximum possible due to land constraints, but there is potential for expansion in Mexico [56][58] Question: What is the expected production volume ramp for Montana and Mexico? - Production is expected to ramp up significantly in 2026, with a goal of reaching 500-plus tons a month, although the process may be bumpy [60] Question: Can you quantify efficiencies or technological improvements in processing? - There will be some mechanical efficiencies with the expansion, but the type of feed material will also significantly impact efficiency [64] Question: How close are current smelting operations to running at full capacity? - Montana is running close to capacity, but quality issues with material have been a challenge, which the company is addressing [65][66]

Financial Data and Key Metrics Changes - Sales for the first nine months of 2025 were $26.2 million, up $16.9 million, or 182% over the prior year, primarily due to price increases and some volume increase in the zeolite business [6][7] - Gross margin increased by 4 percentage points from 24% last year to 28% this year, although there will be pressure on gross margins in the fourth quarter due to declining antimony market prices [6][7] - Consolidated net loss was $4.1 million for the first nine months, including $5.2 million of non-cash expenses, but operating activities generated positive cash flow when excluding working capital changes [7][8] Business Line Data and Key Metrics Changes - Antimony sales volume increased in October, with consolidated sales of $5.6 million for the month compared to third quarter sales of $8.7 million [6][7] - The company secured a three-year supply agreement for antimony ore and a five-year sole source sales contract with the DLA, enhancing sales capabilities [9][10] Market Data and Key Metrics Changes - The company has developed and executed over 15 separate supply contracts for materials sourced from 10 different countries, with significant developments in Bolivia and Chad expected to support antimony production [28][29] - The market cap expanded almost fourfold from around $200 million to more than $1 billion since the start of 2025, with a significant increase in institutional ownership [35][36] Company Strategy and Development Direction - The company aims to be the preferred provider of critical minerals, focusing on growth, diversification, and sustainability [9][10] - Plans to duplicate antimony success in tungsten and cobalt, with ongoing discussions with the U.S. government for potential funding and support [24][30] - The company is expanding its processing facility in Montana, with completion expected in January 2026, which will significantly increase production capacity [32][44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating a ramp-up in production from 100 tons to 500-600 tons per month, driven by new supply contracts and operational improvements [32][60] - The company highlighted the strategic importance of domestic antimony production in light of geopolitical tensions and reliance on foreign sources, particularly China [49][50] Other Important Information - The company has made significant progress in securing long-term sales agreements, totaling $352 million, which is a substantial increase compared to previous revenues [41][42] - The company is the only vertically integrated antimony supplier outside of China and Russia, positioning itself uniquely in the market [43] Q&A Session Summary Question: What is the difference between the two types of antimony? - The DLA contract is for metallic antimony in ingot form, while the commercial supply contract is for antimony trioxide, a white powder [51][54] Question: Is management considering building an additional smelter or processing facility? - The current expansion in Thompson Falls is the maximum possible due to land constraints, but there is potential for expansion in Mexico [56][58] Question: What is the expected production volume ramp for Montana and Mexico? - Production is expected to ramp up significantly in 2026, with a goal of reaching 500 tons per month, although there may be challenges along the way [59][60] Question: Can you quantify efficiencies or technological improvements in processing? - The expansion will include larger equipment and improved technologies, which should enhance efficiency, but the quality of feed material will also play a crucial role [61][64] Question: How close are current smelting operations to running at full capacity? - Montana operations are running near capacity, but quality issues with material from Madero have been a challenge [65][66] Question: What has been spent on expanding capacity at smelting operations? - Total CapEx is around $22 million, with approximately $12-13 million already spent [67][68]

Financial Data and Key Metrics Changes - Sales for the first nine months of 2025 were $26.2 million, an increase of $16.9 million, or 182% compared to the previous year [6] - Gross margin increased by 4 percentage points from 24% last year to 28% this year [7] - Consolidated net loss was $4.1 million for the first nine months, including $5.2 million of non-cash expenses [8] - Cash investments at the end of Q3 2025 were $38.5 million, an increase of $20 million from the previous year [9] Business Line Data and Key Metrics Changes - Antimony sales volume increased in October, contributing to a consolidated sales figure of $5.6 million for that month [7] - The company secured a three-year supply agreement for antimony ore and a five-year sole source sales contract with the Defense Logistics Agency [10] Market Data and Key Metrics Changes - The company reported a significant increase in market capitalization, rising from around $200 million to over $1 billion since the start of 2025 [36] - The share price climbed from about $3.08 to $6.20 during Q3 2025, marking a more than 100% increase [36] Company Strategy and Development Direction - The company aims to become a preferred provider of critical minerals, focusing on growth, diversification, and sustainability [10] - Plans include expanding mining operations in Montana, Alaska, and Ontario, with a focus on antimony and other critical minerals [12][20] - The company is exploring opportunities in Bolivia and Chad to diversify its supply chain [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating a significant ramp-up in production capacity from 100 tons to 500-600 tons per month [34][61] - The company is focused on generating positive cash flow and creating a solid foundation for future growth [10] - The strategic importance of domestic antimony production was emphasized, particularly in light of geopolitical tensions and supply chain security [50] Other Important Information - The company has engaged in significant investor relations activities, resulting in increased institutional ownership from almost zero to about 30% [36] - The company is the only vertically integrated antimony supplier outside of China and Russia, with no direct competition in North America [44][45] Q&A Session Summary Question: What is the difference between the two types of antimony in the contracts? - The DLA contract is for metallic antimony in ingot form, while the commercial supply contract is for antimony trioxide, a white powder [54] Question: Is management considering building an additional smelter or processing facility? - Current expansion efforts in Thompson Falls are maxed out due to land constraints, but there is potential for expansion in Mexico [56][58] Question: What is the expected production volume ramp for Montana and Mexico? - Anticipated ramp-up to 500-plus tons a month by the end of 2026, with challenges in material quality affecting output [60][61] Question: Can you quantify efficiencies or technological improvements in processing? - There will be some mechanical efficiencies with new equipment, but the quality of feed material will significantly impact overall efficiency [62] Question: How close are current smelting operations to running at full capacity? - Montana operations are running near capacity, but quality issues with material from Madero have been a bottleneck [65]

Financial Data and Key Metrics Changes - Average production increased by 40% to 4,254 barrels of oil equivalent (BOE) per day compared to 3,032 BOE per day in the prior year quarter [6][7] - Revenue rose by 15% to $15 million in Q3 2025, driven by higher production, despite an 18% decline in prices [6][7] - Adjusted EBITDA reached $11.1 million, a 9% increase from the prior quarter [7] - Net income decreased to $3.6 million, with basic EPS of $0.10 per share, down from $5.1 million or $0.14 per share in the prior year quarter [7][9] - Operating expenses were $7.37 per BOE, an 11% increase from the prior year, primarily due to reassessed production tax adjustments [8][10] Business Line Data and Key Metrics Changes - The company is in the process of fracture stimulating four new wells expected to come online in early December, which will further increase production [5][11] - The average production for the nine months ended September 30th was up 22% to 3,851 BOE per day compared to 3,154 BOE per day in the prior year [9] Market Data and Key Metrics Changes - Net back for the quarter decreased by 23% to $30.84 per BOE compared to $40.01 per BOE in the prior year quarter, primarily due to lower prices [8] - Year-to-date revenue was up 2% to $42.1 million, despite a 16% decrease in prices [9] Company Strategy and Development Direction - The company plans to continue returning capital to shareholders through share buybacks, having repurchased approximately 568,000 shares since the program began [10][12] - Future drilling programs will depend on oil prices, with a focus on maintaining flat production levels if prices remain low [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record high production by the end of the year, despite lower oil prices [12] - The company is monitoring the Forgeson well's production and will not pursue further drilling in that area unless prices improve [20][21] - Management indicated that the current hedging strategy reflects the volatile market conditions, aiming to protect against downside risks while allowing for potential upside [24] Other Important Information - The company reaffirmed its line of credit at $65 million, with net debt at $42.8 million and $18.5 million of available borrowing capacity [10] - The one-time production tax adjustment was clarified as a non-recurring event, which impacted operating expenses [25][26] Q&A Session Summary Question: Timing of the four new wells - Management confirmed that production from the new wells is expected to commence in early December [15] Question: Changes to guidance and leverage expectations - Management indicated that they remain comfortable with expectations of around one-times net leverage by year-end [18] Question: Update on the Forgeson well and future drilling plans - Production from the Forgeson well has been flat, and further drilling in that area is unlikely unless oil prices improve [20] Question: October hedging strategy - The shift in hedging strategy was due to unfavorable forward pricing, with a focus on protecting against downside risks while allowing for potential upside [24] Question: Explanation of higher operating expenses - The increase in operating expenses was attributed to a one-time true-up of production taxes, which is not expected to recur [25][26]

Financial Data and Key Metrics Changes - The meeting confirmed that a quorum was present with approximately 71.32% of shares entitled to vote represented [4][5]. - Preliminary voting results indicated that all nominees for the Board of Directors were elected, and the fiscal 2025 compensation of named executive officers was approved on an advisory basis [8]. Business Line Data and Key Metrics Changes - No specific data regarding individual business lines was provided during the meeting [12]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting [12]. Company Strategy and Development Direction and Industry Competition - The meeting did not provide detailed insights into the company's strategic direction or competitive landscape [12]. Management's Comments on Operating Environment and Future Outlook - Management did not offer specific comments regarding the operating environment or future outlook during the meeting [12]. Other Important Information - The appointment of Grant Thornton as the company's independent registered public accounting firm for fiscal 2026 was ratified [8]. Q&A Session All Questions and Answers Question: Are there any questions from the attendees? - There were no questions submitted during the Q&A session [12].

Financial Data and Key Metrics Changes - In Q3 2025, the company recorded revenue of $800,000 from R&D services, compared to no revenue in Q3 2024, reflecting a significant increase in activity [18] - Operating expenses for Q3 2025 were $15.3 million, up from $14.2 million in Q3 2024, primarily due to higher R&D costs [19] - The net loss for Q3 2025 was $13.3 million, an increase from $11.2 million in Q3 2024, but flat compared to Q2 2025 [20] Business Line Data and Key Metrics Changes - The KARNO Power Module has achieved over 200 kilowatts of mechanical power and more than 150 kilowatts of electrical power generation, meeting the needs of initial customers [5][6] - The company has confirmed that the KARNO Power Module meets stringent air quality standards, achieving NOx levels below 2.5 parts per million [6][7] - The UL certification process for the KARNO Power Module is progressing well, with testing requirements for the linear electric motor passed on the first attempt [9] Market Data and Key Metrics Changes - Customer interest in the KARNO Power Module remains strong, with nearly 500 units under non-binding letters of intent [12] - The company is deepening engagement with the U.S. military for energy security applications, with plans to deliver additional KARNO Power Modules for specialized testing in 2026 [13] - The data center market is increasingly adopting 800-volt DC architectures, aligning with the KARNO Power Module's native output [15][46] Company Strategy and Development Direction - The company is focused on transitioning from R&D to commercialization of the KARNO Power Module, with full commercialization expected in 2026 [12][22] - Strategic decisions were made to implement design improvements before UL certification to avoid future recertification [42] - The company is exploring partnerships in the nuclear sector to enhance the efficiency of next-generation nuclear systems [14][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the performance of the KARNO Power Module and its alignment with market needs, particularly in data centers and military applications [24] - The company anticipates being supply-constrained due to strong demand for the KARNO system across multiple sectors [12][35] - Management highlighted the importance of optimizing existing manufacturing capabilities while planning for future expansions [40] Other Important Information - The company expects total cash expenditures of $65 million for 2025, with a year-end cash and investment balance projected at approximately $155 million [21][23] - A 30% tax credit for the KARNO Power Module is expected to accelerate adoption and support commercial ramp-up [18] Q&A Session Summary Question: What vertical is the customer that shifted its acceptance of the initial KARNO units from 2025 into 2026? - The customer is the Navy, with the unmanned ship scheduled to have KARNO units installed in 2026 [25][26] Question: When will all the UL testing be completed? - The completion of UL testing is expected in the next couple of months, with multiple phases of certification [30] Question: Can you provide context around the 500 units in LOI? - The 500 units represent dozens of customers, with a strong demand for the product and ongoing discussions with new potential customers [33][35] Question: How is the company addressing manufacturing scale-up challenges? - The company has brought production in-house and is focused on optimizing existing manufacturing processes while planning for future expansions [39][40]